Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) Director Jan Skvarka sold 5,000 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $25.05, for a total transaction of $125,250.00. Following the transaction, the director now directly owns 47,970 shares of the company’s […]
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Get Free Report) has received an average rating of “Buy” from the seven ratings firms that are currently covering the stock, Marketbeat reports. Seven analysts have rated the stock with a buy rating. The average twelve-month price objective among brokerages that have covered the stock in the last year is […]
Sectoral Asset Management Inc. Purchases 33,000 Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
01.09.2023 - NEW YORK and SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) - Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting .